This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 May;14(5):262-263.

doi: 10.1038/nrclinonc.2017.33. Epub 2017 Mar 7.

Targeted therapies: Reversal of fortunes for TKI resistance

PMID: 28266520
DOI: 10.1038/nrclinonc.2017.33

Comment

Targeted therapies: Reversal of fortunes for TKI resistance

Louise Stone. Nat Rev Clin Oncol. 2017 May.

. 2017 May;14(5):262-263.

doi: 10.1038/nrclinonc.2017.33. Epub 2017 Mar 7.

Author

PMID: 28266520
DOI: 10.1038/nrclinonc.2017.33

No abstract available

PubMed Disclaimer

Comment on

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Aggarwal R, et al. J Clin Oncol. 2017 Apr 10;35(11):1231-1239. doi: 10.1200/JCO.2016.70.5350. Epub 2017 Feb 21. J Clin Oncol. 2017. PMID: 28221861 Free PMC article. Clinical Trial.

References

1. J Clin Oncol. 2017 Apr 10;35(11):1231-1239 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations